Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, proxalutamide significantly reduced the 30-day hospitalization rate by 91% compared to placebo in men with COVID-19 treated in outpatient settings.

In this randomized controlled trial, daily use of a hair serum containing plant extracts and manganese PCA improved scalp tightness, reduced discomfort, and enhanced hair growth quality in men post-hair transplant, suggesting its efficacy as a dermocosmetic adjuvant for long-term hair care.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

This study found that platelet-rich plasma injections significantly increased hair count and density in patients with male pattern hair loss without major side effects, suggesting it may be a safe and effective treatment option.

This study reported that both phlebotomy and oral contraceptive pills with cyproterone acetate effectively improved insulin resistance and androgenic profiles in women with PCOS, but OCs had more impact on regularizing menstrual cycles.

In this randomized controlled study, the researchers found that an herbal extract combination showed similar efficacy to 3% minoxidil solution in treating androgenetic alopecia over 24 weeks, with no significant safety concerns, suggesting it might be a viable alternative treatment.

This study examined the preservative and antimicrobial susceptibility of non-fermenting bacilli collected from beauty salon waste in Brazil.

In this pilot study, both tofacitinib and methotrexate improved alopecia areata outcomes, but tofacitinib showed greater efficacy in achieving significant SALT score improvement after 6 months, although the difference was not statistically significant.

This study found that platelet-rich plasma injections significantly increased hair density in men with androgenetic alopecia compared to placebo, but further research is needed to understand factors influencing treatment success.

This study reported that among obese women with PCOS, neither early time-restricted eating (eTRE) alone nor combined with probiotics showed significant improvements in blood pressure, inflammatory markers, oxidative stress, or antioxidant capacity compared to a standard reduced-calorie diet.

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

This study found that FDA-approved low-level light/laser therapy devices significantly increased hair density in individuals with pattern hair loss compared to sham devices.

This review discusses the limited evidence on the efficacy of platelet-rich plasma for treating endocrine therapy-induced and permanent chemotherapy-induced alopecia and reports no new clinical results.

In this study, AMP-303 injections demonstrated a trend toward increasing non-vellus hair count in men with mild to moderate androgenetic alopecia, notably showing a 14.5% peak increase at 60 days compared to saline, with effects lasting up to five months.

Platelet-rich plasma helps hair regrowth and improves quality of life in women with hair loss, but minoxidil may be more effective.

In this study, platelet-rich plasma significantly increased hair regrowth and reduced symptoms of alopecia areata compared to triamcinolone acetonide or placebo, with no observed side effects.

This study suggests that antiandrogens may slightly reduce hirsutism severity compared to placebo, but evidence is weak and their relative efficacy remains uncertain.

This study found that spinach-derived thylakoid supplementation, combined with a calorie-restricted diet, led to more significant improvements in weight loss and insulin sensitivity in obese women with PCOS than calorie restriction alone.

In this study, microneedle combined with 5% topical minoxidil significantly increased hair count in androgenetic alopecia, suggesting it as a potential additional therapy option; however, microneedle alone had limited effects.

In this study, researchers reported that an herbal extract with dihydroquercetin glucoside, epigallocatechin gallate glucoside, zinc, and glycine showed similar effectiveness and safety to minoxidil in treating androgenetic alopecia over 24 weeks, with no significant differences in hair growth outcomes between the groups.

The device improved hair growth and thickness in men without side effects.

This review reports that while ginseng's safety profile seems favorable, the evidence for its clinical efficacy remains limited due to generally poor study quality in the included Korean randomized trials.

This study found that treatment with the synbiotic SIM01 significantly alleviated multiple symptoms of post-acute COVID-19 syndrome compared to placebo, suggesting potential management benefits through gut microbiome modulation.

This study concluded that platelet-rich plasma is effective and safe for increasing hair density in androgenetic alopecia, showing significant improvement compared to placebo at 3 and 6 months.

This study assessed the effectiveness of various combinations of minoxidil with other agents for androgenetic alopecia, finding that platelet-rich plasma and basic fibroblast growth factor combined with minoxidil significantly increased hair density, while different combinations were optimal depending on gender.

In this phase 1B clinical trial, sublingual minoxidil was tested for its effects on male and female pattern hair loss in a randomized, double-blind, placebo-controlled setting, but the abstract does not provide specific results or conclusions.

This study found that a cream containing 6.0% Stryphnodendron adstringens bark extract effectively reduced terminal hair growth and improved skin conditions in women with excessive terminal hair.

Insulin sensitizers may slightly reduce hirsutism but are less effective than other treatments.

This review found that low-level laser therapy significantly increased hair density in adults with androgenic alopecia compared to sham treatments, with greater effects observed at lower treatment frequencies.

This study found that recruiting healthy naturally menopausal women for a DHEA therapy trial was challenged by concerns about hormonal treatments and time constraints, impacting study feasibility.